Steve Albers is Senior Vice President, Market Access and Public Affairs for Novo Nordisk Inc. since November 2020. Steve leads the US Market Access team in setting strategies and providing national leadership in communicating the value of all Novo Nordisk products to …

Novo Nordisk’s product portfolio includes several injectable medications (in both vial and pen device) that require the use of needles, as well as pen needles. More information about Novo Nordisk and our products available in the United States can be found by visiting https://www.nnpi.com.

Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.

Novo Nordisk also offers a free of charge home generated medical sharps containment and disposal system to CA and MN residents using our product portfolio. These services are also made available by Novo Nordisk to patients in other states. Patients may visit

Learn about the Novo Nordisk Industry Practice PharmD Fellowship, a competitive postdoctoral opportunity for recent PharmD graduates. View information about the program here.

Novo Nordisk offers a free of charge home generated medical sharps containment and disposal system to CA residents using our product portfolio. Patients may visit http://www.novocare.com/needledisposal

Novo Nordisk is a member of the Pharmaceutical Product Stewardship Work Group (PPSWG). As part of PPSWG, Novo Nordisk supports PPSWG efforts to comply with local requirements regarding the collection and disposal of sharps.

In this role, you will be joining a newly established and growing area in our company, responsible for designing, planning, and building all major fill & finish expansion projects across Novo Nordisk to meet the needs of millions of patients.

PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …

Dec 7, 2024 · "At Novo Nordisk, we have a 35+ year legacy and expertise in hematology and rare disease, and our ambition is to transform the standard of care for people with sickle cell disease by developing treatments that not only alleviate symptoms but also modify the course of the disease," said Martin Holst Lange, executive vice president and head of ...